Drug-resistant tuberculosis (TB) is a consistently growing threat to global health. We have developed Oxy291, a new, orally available antibiotic that targets both active and dormant (persistent) TB bacteria. This project will test Oxy291 in mice to determine if it can safely and effectively reduce TB infection, paving the way for developing faster, more effective treatments.